Vitro Diagnostics Release: New Results Reveal Extensive Competitive Advantages of VitroGrow(TM) Stem Cell Culture Media

Published: Dec 15, 2010

GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG) (OTCQB: VODG), dba Vitro Biopharma, announced completion of studies comparing its mesenchymal stem cell culture media, VitroGrow™, to major competitors showing distinct performance improvements over competing products. These new results showed that VitroGrow™ consistently improved mesenchymal stem cell growth, quality, potency and cellular recovery over leading competitors including comparable products sold by InVitrogen, Lonza and Stem Cell Technologies. Furthermore, VitroGrow™ also exhibits real-time stability that exceeds 1 year while competitors published recommended usage periods are 2 weeks to 4 weeks, thus resulting in substantial cost savings and expanded usage opportunities to VitroGrow™ customers.

Back to news